D. Haraf

发表

p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines.

D. Brachman, R. Weichselbaum, E. Vokes, 1993, Cancer research.

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.

E. Vokes, T. Seiwert, D. Haraf, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer.

R. Weichselbaum, F. T. Kuchnir, D. Haraf, 1995, International journal of radiation oncology, biology, physics.

Initial clinical experience with a video-based patient positioning system.

G T Chen, C A Pelizzari, C. Pelizzari, 1999, International journal of radiation oncology, biology, physics.

Volumetric visualization of anatomy for treatment planning.

G T Chen, G. Chen, R. Grzeszczuk, 1996, International journal of radiation oncology, biology, physics.

How D o H ead a nd N eck C ancer P atients P rioritize Treatment O utcomes B efore I nitiating T reatment

E. Vokes, D. Haraf, L. Colangelo, 2000 .

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

E. Vokes, A. Argiris, D. Haraf, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of radiotherapy with or without chemotherapy on tongue strength and swallowing in patients with oral cancer

A. Rademaker, E. Vokes, C. Lazarus, 2007, Head & neck.

Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment.

R. Weichselbaum, E. Vokes, D. Haraf, 2004, International journal of oncology.

Swallowing function in patients with head and neck cancer prior to treatment.

R. Weichselbaum, E. Vokes, D. Haraf, 2000, Archives of otolaryngology--head & neck surgery.

Reirradiation of recurrent and second primary head and neck malignancies: a comprehensive review.

D. Haraf, J. Kao, M. Milano, 2003, Cancer treatment reviews.

Phase I study of docetaxel with concomitant thoracic radiation therapy.

E. Vokes, D. Haraf, G. Masters, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Trial of the Oral Platinum Analogue JM216 with Concomitant Radiotherapy in Advanced Malignancies of the Chest

C. Rudin, E. Vokes, D. Haraf, 2004, Investigational New Drugs.

Induction chemotherapy, surgery, and concomitant chemoradiotherapy for carcinoma of the esophagus: a long-term analysis.

E. Vokes, D. Haraf, M. Ferguson, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies.

E. Vokes, D. Haraf, G. Masters, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is Routine Carotid Imaging Warranted Following Radiation Treatment of Head and Neck Cancer

D. Haraf, B. Onderdonk, 2019, Difficult Decisions in Surgery: An Evidence-Based Approach.

Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers.

R. Weichselbaum, E. Vokes, D. Haraf, 2006, International journal of oncology.

Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.

R. Weichselbaum, E. Vokes, A. Argiris, 2005, International journal of radiation oncology, biology, physics.

Reversion of radiosensitivity in azacytidine-treated XRS5 cells does not result in full radioprotection by WR-1065.

D. Haraf, D. Grdina, P. J. Meechan, 1992, International journal of radiation oncology, biology, physics.

Varying levels of radioprotection from the effects of JANUS neutrons in repair-deficient xrs-5 hamster cells treated with azacytidine.

D. Haraf, D. Grdina, P. J. Meechan, 1994, Radiation research.

Magnetic Resonance Imaging Changes in a Head and Neck Cancer Patient with Wernicke Encephalopathy and Visual Loss

D. Haraf, E. Cohen, S. Ksiazek, 2011 .

Concomitant chemoradiotherapy for non-small cell lung cancer.

E. Vokes, D. Haraf, H. Golomb, 1994, Lung cancer.

Phase I Study of Concomitant Chemoradiotherapy with Irinotecan, 5‐FU., and Hydroxyurea for Patients with Advanced and/or Recurrent Head and Neck Cancer

D. Haraf, K. Stenson, M. Milano, 2005, Cancer journal.

Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction

E. Vokes, D. Haraf, M. Ferguson, 1995, Annals of Surgical Oncology.

Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction

E. Vokes, D. Haraf, M. Ferguson, 1995 .

Concomitant chemoradiotherapy with cisplatin, 5‐fluorouracil and hydroxyurea in poor‐prognosis head and neck cancer

W. Panje, R. Weichselbaum, E. Vokes, 1992, The Laryngoscope.

A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer

R. Salgia, E. Vokes, T. Seiwert, 2007, Clinical Cancer Research.

Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.

C. Rudin, E. Vokes, D. Huo, 2002, Lung cancer.

patients and refer them to other institutions with higher energy neutron beams, better collimation, and fewer reported complications.

D. Haraf, S. Maryland, Ralph R. Weehselbaum, 1996 .

Optima: A phase II dose and volume de-escalation trial for high- and low-risk HPV+ oropharynx cancers.

E. Vokes, T. Seiwert, D. Haraf, 2017 .

Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy.

E. Vokes, D. Haraf, E. Cohen, 2013, Journal of geriatric oncology.

Radiation-Induced Leiomyosarcoma: Does Antimetabolite Chemotherapy Contribute? A Report of Three Cases

A. Montag, A. Mundt, D. Haraf, 2003, Sarcoma.

Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy

R. Weichselbaum, E. Vokes, D. Huo, 2009, Head & neck.

Lymph node density—Prognostic value in head and neck cancer

D. Haraf, K. Stenson, E. Blair, 2014, Head & neck.

Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.

E. Vokes, T. Seiwert, D. Haraf, 2016, International journal of radiation oncology, biology, physics.

Mutation Does Not Correlate with Radiosensitivity in 24 Head and Neck Cancer Cell Lines 1

D. Brachman, R. Weichselbaum, M. Beckett, 2006 .

Radiation therapy in the treatment of cervical Cancer: The university of Chicago/Michael reese hospital experience

D. Spelbring, R. Weichselbaum, J. Rader, 1990, Journal of surgical oncology.

Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma

A. Pearson, E. Vokes, T. Seiwert, 2022, British Journal of Cancer.

Characterizing Lymph Node Burden With Elective Unilateral Neck Irradiation in Human Papillomavirus-Positive Tonsil Squamous Cell Carcinoma: Defining the Upper Limits

A. Pearson, E. Vokes, D. Haraf, 2022, Cureus.

Management of Early Head and Neck Cancer in Elderly Patients.

E. Vokes, D. Haraf, M. Jelinek, 2018, Journal of oncology practice.

A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and

E. Vokes, T. Seiwert, D. Haraf, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.

W. Panje, R. Weichselbaum, E. Vokes, 1992, Journal of the National Cancer Institute.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

E. Vokes, T. Seiwert, D. Haraf, 2019, Annals of Oncology.

Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation

E. Vokes, T. Seiwert, K. Choe, 2011, Cancer.

Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.

E. Vokes, D. Haraf, J. Kao, 2006, International journal of radiation oncology, biology, physics.

Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer.

R. Weichselbaum, E. Vokes, D. Haraf, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer.

R. Weichselbaum, E. Vokes, D. Haraf, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Aspiration in chemoradiated patients with head and neck cancer.

E. Vokes, D. Haraf, K. Stenson, 2007, Archives of otolaryngology--head & neck surgery.

Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.

A. Rademaker, R. Weichselbaum, E. Vokes, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck

E. Vokes, A. Argiris, D. Haraf, 2004, Clinical Cancer Research.

Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.

M. Ratain, S. Lippman, R. Stupp, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Free-Flap Reconstruction in the Doubly Irradiated Patient Population

L. Gottlieb, E. Vokes, D. Haraf, 2008, Plastic and reconstructive surgery.

Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer

E. Vokes, D. Haraf, K. Stenson, 2011, American journal of clinical oncology.

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.

M. Ratain, R. Weichselbaum, E. Vokes, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.

R. Weichselbaum, E. Vokes, D. Haraf, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiation for patients with advanced oral cavity cancer

E. Vokes, D. Haraf, E. Cohen, 2009, The Laryngoscope.

Cellular and molecular mechanisms of radioresistance.

D. Brachman, D. Hallahan, R. Weichselbaum, 1995, Cancer treatment and research.

The evolving role of systemic therapy in carcinoma of the lung.

E. Vokes, D. Haraf, D. Ihde, 1992, Seminars in oncology.

Reirradiation of recurrent head and neck cancers with curative intent.

D. Haraf, M. Milano, S. Chmura, 2004, Seminars in oncology.

Randomized Phase II Study of Paclitaxel ( 1-Hour Infusion ) , Fluorouracil , Hydroxyurea , and Concomitant Twice Daily Radiation with or without Erythropoietin for Advanced Head and Neck Cancer

A. Rademaker, R. Weichselbaum, E. Vokes, 2003 .

Concomitant I nfusional P aclitaxel a nd F luorouracil, O ral Hydroxyurea, a nd H yperfractionate d R adiation f or L ocally Advanced S quamous H ead a nd N eck C ancer

A. Rademaker, R. Weichselbaum, E. Vokes, 2001 .

Reply to s. Chakraborty et al.

E. Vokes, D. Haraf, T. Karrison, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

We appreciate the comments from Chakraborty and Patil 1 re- garding the DeCIDE (Docetaxel Based Chemotherapy Plus or Minus InductionChemotherapytoDecreaseEventsinHeadandNeckCan-

T. Seiwert, D. Haraf, T. Karrison, 2015 .

Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.

E. Vokes, A. Argiris, D. Haraf, 2003, The oncologist.

Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer.

E. Vokes, K. Choe, D. Haraf, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Neuroimaging of Post-treatment and Iatrogenic Conditions Related to the Skin and Subcutaneous Tissues

D. Haraf, D. Ginat, C. Schatz, 2018, Neuroradiological Imaging of Skin Diseases and Related Conditions.

Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation

E. Vokes, C. Lazarus, D. Haraf, 2006, Head & neck.

Adjuvant treatment for high‐risk salivary gland malignancies and prognostic stratification based on a 20‐year single institution experience

E. Vokes, D. Haraf, N. Agrawal, 2020, Health science reports.

Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies

E. Vokes, T. Seiwert, D. Haraf, 2011, Head & neck oncology.

Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.

R. Weichselbaum, E. Vokes, D. Haraf, 1999, Seminars in radiation oncology.

Is It Worth It? Consequences of Definitive Head and Neck Reirradiation.

R. Weichselbaum, N. Lee, S. Yom, 2020, Seminars in radiation oncology.

DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN).

E. Vokes, T. Seiwert, R. Mehra, 2012 .

Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue

E. Vokes, D. Haraf, K. Stenson, 2010, Head & neck.

A phase I study of erlotinib in combination with chemoradiation (CRT) for unresectable, locally advanced non-small cell lung cancer (NSCLC)

E. Vokes, D. Haraf, A. Mauer, 2005 .

A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer

C. Obasaju, R. Salgia, E. Vokes, 2005 .

Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer.

R. Weichselbaum, E. Vokes, D. Haraf, 2001, Cancer journal.

Reirradiation: a potentially curative approach to locally or regionally recurrent head and neck cancer

D. Haraf, M. Garofalo, 2002, Current opinion in oncology.

Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer.

A. Rademaker, R. Weichselbaum, E. Vokes, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.

M. Ratain, E. Vokes, D. Haraf, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

How I do it: Head and neck and plastic surgery: Surgical management of the head and neck cancer patient following concomitant multimodality therapy

W. Panje, R. Weichselbaum, E. Vokes, 1995 .

Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522)

E. Vokes, T. Seiwert, D. Haraf, 2019 .

Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.

J. Bourhis, E. Vokes, D. Haraf, 2007, International journal of radiation oncology, biology, physics.

Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy.

W. Panje, R. Weichselbaum, E. Vokes, 1993, Archives of otolaryngology--head & neck surgery.

Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.

E. Vokes, D. Haraf, E. Cohen, 2013, Oral oncology.

The role of paclitaxel in the treatment of head and neck cancer.

R. Stupp, R. Weichselbaum, E. Vokes, 1995, Seminars in oncology.

Outcomes of Induction Chemotherapy and Concurrent Chemoradiation for Nasopharyngeal Carcinoma

E. Vokes, D. Haraf, E. Cohen, 2012 .

A method of analyzing rectal surface area irradiated and rectal complications in prostate conformal radiotherapy.

D. Spelbring, G. Chen, Srinivasan Vijayakumar, 1995, International journal of radiation oncology, biology, physics.

5-fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study

M. Ratain, R. Weichselbaum, E. Vokes, 2004, Cancer Chemotherapy and Pharmacology.

Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review.

A. Rademaker, E. Vokes, A. Argiris, 2003, International journal of radiation oncology, biology, physics.

Chemoreirradiation for recurrent salivary gland malignancies.

E. Vokes, D. Haraf, K. Stenson, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Planned Post‐Chemoradiation Neck Dissection: Significance of Radiation Dose

E. Vokes, A. Argiris, D. Huo, 2006, The Laryngoscope.

Neck dissection in the combined‐modality therapy of patients with locoregionally advanced head and neck cancer

E. Vokes, A. Argiris, D. Haraf, 2004, Head & neck.

The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection.

R. Weichselbaum, E. Vokes, D. Haraf, 2000, Archives of otolaryngology--head & neck surgery.

Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.

A. Rademaker, E. Vokes, D. Haraf, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

New scoring system identifies kidney outcome with radiation therapy in acute renal allograft rejection.

R. Thisted, D. Haraf, E. Woodle, 2000, International journal of radiation oncology, biology, physics.

Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.

R. Stupp, R. Weichselbaum, E. Vokes, 1995, Seminars in oncology.

How Do head and neck cancer patients prioritize treatment outcomes before initiating treatment?

E. Vokes, D. Haraf, L. Colangelo, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination.

E. Vokes, D. Haraf, K. Stenson, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

E. Vokes, T. Seiwert, R. Mehra, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters.

C. Pelizzari, J. Roeske, R. Weichselbaum, 1990, International journal of radiation oncology, biology, physics.

Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival.

D. Brachman, R. Weichselbaum, A. Montag, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.

A. Pearson, N. Cipriani, E. Vokes, 2021, Oral oncology.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

E. Vokes, T. Seiwert, D. Haraf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictors of competing mortality in advanced head and neck cancer.

R. Weichselbaum, E. Vokes, L. Mell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Performance and quality of life outcome in patients completing concomitant chemoradiotherapy protocols for head and neck cancer

E. Vokes, D. Haraf, R. Mick, 1997, Quality of Life Research.

An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck

E. Vokes, D. Haraf, M. Kies, 2002, Cancer.

Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.

R. Weichselbaum, E. Vokes, D. Haraf, 2006, International journal of oncology.

Sex-associated differences in survival of patients undergoing resection for lung cancer.

E. Vokes, D. Haraf, G. Masters, 2000, The Annals of thoracic surgery.

Is patient travel distance associated with survival on phase II clinical trials in oncology?

E. Lamont, E. Vokes, J. Dignam, 2003, Journal of the National Cancer Institute.

Chemotherapy and High Dose Radiotherapy Followed by Resection for Locally Advanced Nonsmall Cell Lung Cancers

R. Salgia, D. Haraf, M. Ferguson, 2007, American journal of clinical oncology.

Occurrence of p 53 Gene Deletions and Human Papilloma Virus Infection in Human Head and Neck Cancer 1

D. Brachman, R. Weichselbaum, M. Beckett, 2006 .

Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience.

R. Weichselbaum, Srinivasan Vijayakumar, H. Halpern, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.

W. Panje, R. Weichselbaum, E. Vokes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer.

D. Brachman, R. Weichselbaum, E. Vokes, 1992, Cancer research.

Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.

E. Vokes, T. Seiwert, D. Haraf, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Post-Treatment Functional Outcomes.

E. Vokes, T. Seiwert, D. Haraf, 2020, International journal of radiation oncology, biology, physics.

Laparoscopic pelvic lymph node dissection: a review of 103 consecutive cases.

D. Haraf, N. Vogelzang, G. Chodak, 1994, The Journal of urology.

Baseline Computed Tomography Radiomic and Genomic Assessment of Head and Neck Squamous Cell Carcinoma.

Joseph J. Foy, D. Haraf, D. Ginat, 2020, Journal of computer assisted tomography.

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

R. Weichselbaum, E. Vokes, T. Seiwert, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer

R. Weichselbaum, R. Salgia, E. Vokes, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease

R. Weichselbaum, E. Vokes, K. Yenice, 2008, Clinical Cancer Research.

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.

R. Weichselbaum, Helen X. Chen, E. Vokes, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Temporal bone chemodectomas--comparing surgery and radiation therapy.

R. Weichselbaum, D. Haraf, S. Springate, 1991, Oncology.

Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.

A. Rademaker, R. Weichselbaum, E. Vokes, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of pre-treatment CT texture analysis in combination with change in size of the primary tumor in response to induction chemotherapy for HPV-positive oropharyngeal squamous cell carcinoma.

M. Giger, L. Lan, Hui Li, 2019, Quantitative imaging in medicine and surgery.

Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy

E. Vokes, A. Argiris, D. Haraf, 2004, Clinical Cancer Research.

Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.

E. Vokes, D. Haraf, E. Cohen, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer.

R. Salgia, D. Haraf, R. Malik, 2011, Lung cancer.

Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.

E. Vokes, L. Mell, D. Haraf, 2008, Archives of otolaryngology--head & neck surgery.

Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.

A. Rademaker, R. Weichselbaum, E. Vokes, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timing and sequencing of chemoradiotherapy.

R. Weichselbaum, E. Vokes, D. Haraf, 1995, Cancer treatment and research.

Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.

R. Weichselbaum, E. Vokes, D. Haraf, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.

W. Panje, R. Schilsky, R. Weichselbaum, 1992, Seminars in oncology.

Electron-photon field matching in the treatment of paranasal sinus tumors: a case report.

J. Roeske, A. Mundt, F. T. Kuchnir, 1996, Medical Dosimetry.

Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.

E. Vokes, T. Seiwert, D. Haraf, 2018, Oral oncology.

Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results.

R. Weichselbaum, E. Vokes, D. Haraf, 1999, The cancer journal from Scientific American.

Intensive induction chemotherapy followed by concomitant chemoradiotherapy in the management of locoregionally advanced carcinoma of the pyriform sinus.

R. Weichselbaum, E. Vokes, D. Haraf, 2003 .

A Phase II trial of induction Cisplatin, 5-FU, Leucovorin, and Interferon α-2B (PFL-α) followed by concurrent Hydroxyurea, 5-FU and radiation for Stage IV squamous cell cancers of the head and neck (HNC)

W. Panje, R. Weichselbaum, D. Haraf, 1994 .

Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.

W. Panje, M. Ratain, R. Weichselbaum, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin, 5-Fluorouracil and high dose oral Leucovorin (PFL) with Methotrexate and Piritrexim as Neo-Adjuvant chemotherapy for head and neck cancer

W. Panje, R. Weichselbaum, E. Vokes, 1991 .

Efficacy of concomitant chemoradiotherapy in poor prognosis head and neck cancer

W. Panje, R. Weichselbaum, E. Vokes, 1991 .

Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.

R. Weichselbaum, E. Vokes, D. Haraf, 1994, International journal of radiation oncology, biology, physics.

Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.

R. Weichselbaum, E. Vokes, D. Haraf, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I-II study of concomitant chemoradiotherapy with paclitaxel (one-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer.

E. Vokes, D. Haraf, K. Stenson, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.

Olufunmilayo I. Olopade, Mark W. Lingen, Everett E. Vokes, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stereotactic body radiotherapy for multisite extracranial oligometastases

R. Weichselbaum, E. Vokes, K. Yenice, 2012, Cancer.

Complete Radiographic Response Correlates With Pathologic Complete Response in Locoregionally Advanced Head and Neck Cancer

E. Vokes, D. Haraf, K. Stenson, 2015 .

Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy.

E. Vokes, K. Mouw, D. Haraf, 2012, Oral oncology.

Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer.

E. Vokes, D. Haraf, K. Stenson, 2009, Archives of otolaryngology--head & neck surgery.

Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.

A. Rademaker, R. Weichselbaum, E. Vokes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.

A. Pearson, E. Vokes, T. Seiwert, 2021 .

Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer

O. Olopade, J. Dancey, R. Salgia, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Factors associated with long-term speech and swallowing outcomes after chemoradiotherapy for locoregionally advanced head and neck cancer.

Xi Xi, Joseph K Salama, E. Vokes, 2010, Archives of otolaryngology--head & neck surgery.

The use of concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer.

E. Vokes, D. Haraf, M. Kies, 2000, Seminars in oncology.

Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study

E. Vokes, D. Haraf, P. Hoffman, 2004, Cancer Chemotherapy and Pharmacology.

A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.

E. Vokes, D. Haraf, K. Stenson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment selection in T1 and T2 vocal cord carcinoma.

R. Weichselbaum, D. Haraf, 1988, Oncology.

A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer

E. Vokes, T. Seiwert, D. Haraf, 2007, Cancer investigation.

Oral 5-FU alternatives for the treatment of head and neck cancer.

E. Vokes, D. Haraf, R. Humerickhouse, 1998, Oncology.

Combined modality therapy in non-small cell lung and esophageal cancer: a phase I dose-escalation study of docetaxel with concurrent radiotherapy.

E. Vokes, D. Haraf, A. Mauer, 1998, Seminars in oncology.

Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary.

E. Vokes, A. Argiris, D. Haraf, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of bevacizumab (B) with fluorouracil (F) and hydroxyurea (H) with concomitant radiotherapy (X) (B-FHX) for poor prognosis head and neck cancer (HNC).

H X Chen, R. Weichselbaum, E. Vokes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest

E. Vokes, D. Haraf, N. Vogelzang, 1995, Cancer Chemotherapy and Pharmacology.

Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer.

W. Panje, R. Weichselbaum, E. Vokes, 1992, Seminars in oncology.

Reply to With regard to “Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer”, by Oh et al. (Ann Oncol 2003; 14: 564–569)

E. Vokes, D. Haraf, J. Oh, 2004 .

OPTIMA—A Phase 2 Trial of Induction Chemotherapy Response-Stratified Radiation Therapy Dose and Volume De-escalation for HPV+ Oropharyngeal Cancer: Efficacy, Toxicity, and HPV Subtype Analysis

E. Vokes, T. Seiwert, D. Haraf, 2018 .

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer

C. Rudin, E. Vokes, D. Haraf, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Induction Chemotherapy followed by Concomitant TFHX Chemoradiotherapy with Reduced Dose Radiation in Advanced Head and Neck Cancer

R. Weichselbaum, E. Vokes, A. Argiris, 2003 .

Twice-daily re-irradiation of recurrent and second primary head and neck cancer with gemcitabine, paclitaxel and fluorouracil chemoradiotherapy.

R. Weichselbaum, E. Vokes, D. Haraf, 2004, Journal of Clinical Oncology.

Osteoradionecrosis of the jaws as a risk factor in radiotherapy: a report of an eight-year retrospective review.

E. Vokes, D. Haraf, W. Moran, 1998, Oncology Report.

Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.

E. Vokes, D. Haraf, E. Cohen, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.

E. Vokes, D. Haraf, E. Cohen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radioresistant derivatives of an X-ray-sensitive CHO cell line exhibit distinct patterns of sensitivity to DNA-damaging agents.

R. Weichselbaum, J. Schwartz, D. Haraf, 1990, Carcinogenesis.

Radioresistant derivatives of radiosensitive CHO cells obtained following treatment with 5-azacytidine retain their sensitivity to cisplatin.

R. Weichselbaum, D. Haraf, A. Diamond, 1991, Radiation Research.

Measurement of bioreduction rates of cells with distinct responses to ionizing radiation and cisplatin.

R. Weichselbaum, H. Halpern, M. Bowman, 1991, Biochimica et biophysica acta.

Profferred Paper Abstracts: Session C3: Combined Modality Therapy in NSCLC II: Wednesday, September 5: Combined Modality Therapy in NSCLC II, Wed, 10:30 - 12:15C3-01: Phase I Trial of Erlotinib-based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer

E. Vokes, D. Haraf, N. Choong, 2007 .

PD-48 Pemetrexed-based concurrent chemoradiotherapy (CRT)for locally advanced or metastatic non-small cell lung or esophageal cancer: A phase I dose-escalating study

R. Salgia, E. Vokes, T. Seiwert, 2005 .

Phase I Study of Docetaxel and Concomitant Chest Radiation

E. Vokes, D. Haraf, G. Masters, 1997 .

AHNS Series – Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines

E. Vokes, T. Seiwert, D. Haraf, 2017, Head & neck.

Race and competing mortality in advanced head and neck cancer.

R. Weichselbaum, E. Vokes, L. Mell, 2014, Oral oncology.

O-308 A phase I trial of pemetrexed + chest radiotherapy in patients with advanced or metastatic non-small-cell lung cancer or esophageal cancer

C. Rudin, E. Vokes, D. Haraf, 2003 .

Volumetric visualization of head and neck CT data for treatment planning.

G T Chen, C A Pelizzari, A B Jani, 1999, International journal of radiation oncology, biology, physics.

Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.

W. Panje, E. Vokes, M. Collier, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemoradiation for patients with large‐volume laryngeal cancers

E. Vokes, T. Seiwert, D. Haraf, 2012, Head & neck.

A dosimetric study comparing three-, four-, and six- field plans for treatment of carcinoma of the prostate.

D. Brachman, F. T. Kuchnir, D. Haraf, 1992, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

Anaplastic carcinoma of the thyroid.

E. Vokes, D. Haraf, W. Recant, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Survival and Analysis of Failure Following Hydroxyurea, 5‐Fluorouracil and Concomitant Radiation Therapy in Poor Prognosis Head and Neck Cancer

W. Panje, R. Weichselbaum, E. Vokes, 1991, American journal of clinical oncology.

Assessment of Tumor Burden and Response by RECIST vs. Volume Change in HPV+ Oropharyngeal Cancer – An Exploratory Analysis of Prospective Trials

E. Vokes, D. Haraf, E. Izumchenko, 2022, International Journal of Radiation Oncology*Biology*Physics.

Quality of life (QL) and performance outcome in survivors of concomitant chemoradiotherapy protocols for head and neck cancer (HNC) (Meeting abstract).

R. Weichselbaum, E. Vokes, D. Haraf, 1997 .

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

E. Vokes, T. Seiwert, D. Haraf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.

E. Vokes, D. Haraf, G. Masters, 1996, Seminars in oncology.

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

E. Vokes, D. Haraf, M. Lingen, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC).

E. Vokes, D. Haraf, K. Stenson, 2015 .

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

E. Vokes, A. Argiris, D. Haraf, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Clinical Trial.

D. Haraf, R. Hasina, E. Maccracken, 2024, JAMA oncology.